People · Operator
Named in public records as an officer, director or promoter · active 2014–2018 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dermira, Inc. | — | Other Health Care | Series C | $113.0M | $22.9M | 2014 |
| Antiva Biosciences, Inc. | — | Biotechnology | Series B | $96.8M | $457.3M | 2018 |
Wende S. Hutton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Wende S. Hutton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wende Hutton | 2 | 16 |
| EUGENE A. BAUER | 1 | 7 |
| David Kabakoff | 1 | 7 |
| Jake Nunn | 1 | 5 |
| Michael J Sullivan | 1 | 4 |
| David E. Cohen | 1 | 4 |
| Vinzenz Ploerer | 1 | 4 |
| Jake R. Nunn | 1 | 4 |
| Michael Cannon | 1 | 4 |
| Steven James | 1 | 3 |
| Steven P. James | 1 | 3 |
| Eugene Bauer | 1 | 3 |
| Thomas G. Wiggans | 1 | 3 |
| Fred B. Craves | 1 | 3 |
| Matthew K. Fust | 1 | 3 |
| Jenny Yip | 1 | 3 |
| Thomas Wiggans | 1 | 3 |
| Mark D. McDade | 1 | 3 |
| Benjamin Rovinski | 1 | 3 |
| Fred Craves | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.